1084893-56-0

(S)-CR8 is a second generation derivative of (R)-roscovitine and an inhibitor of cyclin-dependent kinase 1 (Cdk1/cyclin B), Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p25, and Cdk9/cyclin T (IC₅₀s = 0.15, 0.08, 0.06, 0.12, and 0.11 μM, respectively). It also inhibits casein kinase CK1δ/ε (CKδ/ε) and DYRK1A (IC₅₀s = 0.61 and 0.9 μM, respectively). (S)-CR8 reduces cell viability in human neuroblastoma cell lines, including SH-SY5Y, SK-N-AS, SK-N-BE, and IMR32 cells (IC₅₀s = 0.43, 1.46, 0.13, and 0.14 μM, respectively). It also reduces protein levels of the survival factor Mcl-1 in SH-SY5Y cells.

(S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective CDK inhibitor with IC50s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC50 0.40?μM)[1].

ChEBI: (2S)-2-[[9-propan-2-yl-6-[[4-(2-pyridinyl)phenyl]methylamino]-2-purinyl]amino]-1-butanol is a phenylpyridine.

Store at -20°C

[1] K Bettayeb, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008 Oct 2;27(44):5797-807. DOI:10.1038/onc.2008.191